drugset / Trial / NCT01108731

The Effect of Milnacipran in Patients With Fibromyalgia

NCT01108731

Phase 2/3 Completed 37 enrolled Beth Israel Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.

Timeline

Start
2010-03
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Milnacipran Other / unclassified 50 mg

Indications